Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENX-201 3-way crossover PK/PD study in healthy volunteers
NL-OMON46131Completed
- Sponsor
- EnhanX Biopharm
- Start
- Oct 2018
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, double-blind trial of ENX-201 in multiple sclerosis (MS) (3 arms), sponsored by EnhanX Biopharm. Primary endpoints: MPhs plasma concentrations, MP plasma concentrations and 2 more. Started Oct 2018; status: completed.
02
Drugs
ENX-201
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON46131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46131.